Skip to main content

Find Clinical Trials

Home
Conditions
Peripheral T-cell Lymphoma

Clinical trial condition

Peripheral T-cell Lymphoma

Explore clinical trials studying Peripheral T-cell Lymphoma. Study availability and eligibility vary by location and protocol.

100 public trials 16 recruiting studies

Refine in advanced search Browse all conditions

Peripheral T-cell Lymphoma trial results

Completed

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

NCT01611142

Conditions: Hematologic Diseases, Hematologic Neoplasms, Hemic and Lymphatic Diseases, +12 more
Locations: Aarhus University Hospital Aarhus, Denmark

CHU Henri Mondor Créteil, France

CHRU Lille Lille, France

Hopital Saint-Louis Paris, France

View all 15 locations

View Trial Details

Completed

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

NCT01226472

Conditions: Cutaneous T-Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations: Stanford University Stanford, California, United States

View Trial Details

Completed

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

NCT00888927

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Ronald Reagan UCLA Medical Center Los Angeles, California, United States

Stanford Medical Center Stanford, California, United States

Yale Comprehensive Cancer Center New Haven, Connecticut, United States

H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States

View Trial Details

Completed

Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

NCT01588015

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, +198 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Completed

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

NCT02168140

Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, +40 more
Locations: Comprehensive Cancer Center of Wake Forest University Winston-Salem, North Carolina, United States

Abramson Cancer Center Philadelphia, Pennsylvania, United States

View Trial Details

Completed

Immune Responses to COVID-19 Vaccination in Lymphoma Patients

NCT04858568

Conditions: Burkitt Lymphoma, Chronic Disease, Chronic Lymphocytic Leukemia, +42 more
Locations: Bedfordshire Hospitals NHS Foundation Trust Bedford, Bedfordshire, United Kingdom

Portsmouth Hospitals University NHS Trust Portsmouth, Hampshire, United Kingdom

University Hospital Southampton NHS Foundation Trust Southampton, Hampshire, United Kingdom

Wye Valley NHS Trust Hereford, Herefordshire, United Kingdom

View Trial Details

Completed

A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT02653976

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Hong Kong

Nagoya, Aichi-ken, Japan

Yoshida-gun, Fukui, Japan

Isehara, Kanagawa, Japan

View all 24 locations

View Trial Details

Completed

Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

NCT01523223

Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), +82 more
Locations: Stanford University Stanford, California, United States

View Trial Details

Completed

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

NCT00571662

Conditions: Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Blood Protein Disorders, +40 more
Locations: University of Nebraska Medical Center, Section of Oncology/Hematology Omaha, Nebraska, United States

View Trial Details

Completed

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

NCT01336933

Conditions: Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hemic and Lymphatic Diseases, +15 more
Locations: Mayo Clinic, Arizona Scottsdale, Arizona, United States

Stanford University Stanford, California, United States

Emory University School Of Medicine Atlanta, Georgia, United States

University of Chicago Chicago, Illinois, United States

View Trial Details